Neonatal Heart Failure in China: Burden Rises as Mortality Clues Stay Elusive

Heart failure in the first weeks of life is one of the most feared presentations in neonatal medicine. A newborn’s heart may be struggling for reasons that range from structurally malformed anatomy to overwhelming infection, and the window for effective intervention is measured in hours rather than days. Yet for all its clinical urgency, neonatal heart failure has remained surprisingly poorly mapped. Most epidemiological research lumps infants of all ages together, obscuring the distinct biology, causes, and outcomes that characterize the earliest days of life. A new study published in BMC Pediatrics by researchers at the Children’s Hospital of Chongqing Medical University sets out to close that gap, combining three decades of global disease estimates with detailed clinical data from dozens of hospitals across China.

The investigation took a two-pronged approach. On the population side, the team mined the Global Burden of Disease 2021 results tool, selecting heart failure as a Level 1 impairment and then restricting the analysis to the neonatal period, the first twenty-eight days of life. This yielded prevalence and years lived with disability estimates for Chinese newborns stretching from 1990 to 2021. On the clinical side, the researchers performed a secondary analysis of a pre-existing pediatric heart failure cohort that had enrolled patients at thirty centers spanning twenty Chinese provinces between 2013 and 2022. From that larger cohort, they isolated 212 neonates, of whom 23 died in hospital, and asked which baseline characteristics were associated with those deaths.

The population-level findings paint a picture of modest but persistent growth. Between 1990 and 2021, the prevalence of neonatal heart failure in China rose by 8.64 percent, while the rate of years lived with disability, a measure that captures the functional burden of disease, increased by 8.57 percent. Both metrics showed an estimated annual percentage change of 0.38 percent, indicating a slow, steady climb rather than any dramatic surge. That trajectory likely reflects a combination of forces: improved survival of critically ill newborns who subsequently live with cardiac impairment, better recognition and diagnosis of heart failure in neonatal units, and shifting patterns of underlying disease across three decades of rapid health-system change in China.

Perhaps the most consequential epidemiological finding concerns causation. In 2021, complex congenital heart anomalies emerged as the leading contributing cause of neonatal heart failure in China. This matters because it defines where resources must flow. Structural heart disease in newborns demands surgical and catheter-based interventions, specialized cardiac intensive care, and prenatal detection programs that can route expectant mothers to equipped centers before delivery. A burden dominated by congenital anomalies is fundamentally different from one dominated by cardiomyopathy or infection, and the Chinese data suggest that the structural component now sits at the top of the list.

The clinical half of the study, however, delivers a more sobering message about prediction. The researchers focused on four clinically selected baseline variables: postnatal age, gestational age, the presence of a complex congenital heart anomaly, and severe infection at admission. Because 23 deaths among 212 patients is a small number of events for statistical modeling, they used a Firth penalized logistic regression, a technique designed to produce more stable estimates when outcomes are rare and conventional maximum-likelihood methods can fail. The primary complete-case analysis included 184 neonates and all 23 deaths, with additional analyses addressing missing data, the clustering of patients within centers, and internal validation of the model’s performance.

The point estimates told an intuitively plausible story. Each additional day of postnatal age was associated with lower odds of in-hospital death, with an odds ratio of 0.95, and each additional week of gestational age carried an odds ratio of 0.92, suggesting that more mature and older newborns fared somewhat better. Conversely, complex congenital heart anomalies roughly doubled the odds of death, with an odds ratio of 2.28, and severe infection at admission raised the odds by a factor of 2.68. But here lies the study’s central caveat: every one of those confidence intervals crossed the null value of one. The interval for postnatal age ran from 0.89 to 1.01, for gestational age from 0.80 to 1.05, for complex anomalies from 0.68 to 7.59, and for severe infection from 0.81 to 8.94. In plain terms, the data cannot rule out the possibility that none of these factors is truly associated with mortality.

The authors are refreshingly candid about this limitation, describing the associations as imprecisely estimated and explicitly framing them as exploratory. They caution that larger, prospectively characterized cohorts are needed before any of these variables can be used for risk stratification at the bedside. That caution is well placed. In rare-outcome research, wide confidence intervals are not a technical footnote; they are the difference between a finding that can guide clinical decisions and one that merely generates hypotheses for the next study. A clinician reading these results should come away informed about what is uncertain, not reassured by the direction of the point estimates.

What the model did achieve was respectable discrimination. The apparent area under the receiver operating characteristic curve, a measure of how well the model separates those who die from those who survive, was 0.736, with a bootstrap confidence interval of 0.628 to 0.832. After correcting for optimism, the statistical inflation that occurs when a model is evaluated on the same data used to fit it, the AUC settled at 0.695. That optimism-corrected figure sits in the range often considered acceptable for a parsimonious four-variable model, though it falls short of the performance that would justify deployment as a standalone triage tool. It suggests the chosen variables carry real signal, but that signal is diluted by small numbers and by the heterogeneity inherent in a condition with many causes.

The methodological architecture of the study deserves attention in its own right. Secondary analyses of existing cohorts are an efficient way to extract clinical insight from data already collected, and the researchers layered on the safeguards that such analyses require: multiple imputation or sensitivity handling of missing values, accounting for the fact that patients nested within the same hospital share institutional practices, and bootstrap-based internal validation rather than the naive presentation of uncorrected performance statistics. Pairing this clinical modeling with the GBD 2021 framework also demonstrates a template for rare pediatric conditions worldwide, where dedicated national registries are scarce but global burden estimates and multicenter hospital cohorts can be combined to triangulate both the size of a problem and its determinants.

The broader implications reach beyond China. Neonatal heart failure sits at the intersection of congenital cardiology, neonatal intensive care, and infectious disease, and the finding that complex congenital anomalies now lead the causal profile underscores the importance of prenatal screening, timely referral, and equitable access to pediatric cardiac surgery. Meanwhile, the mortality analysis, though inconclusive, flags severe infection at admission as a factor worth watching, consistent with the well-established interplay between sepsis and cardiac dysfunction in newborns. For researchers, the message is clear: the questions are well posed, the analytical tools are available, and what is needed now is scale. A prospective cohort large enough to yield dozens or hundreds of neonatal deaths would transform these wide, uncertain intervals into estimates sharp enough to build genuine risk scores. Until then, the study stands as both a valuable map of the epidemiological terrain and an honest acknowledgment of how much remains unmapped in the care of the smallest hearts.

Subject of Research: Epidemiology and in-hospital mortality risk factors of neonatal heart failure in China

Article Title: Epidemiological profile and factors associated with in-hospital mortality in neonatal heart failure: a secondary analysis of GBD 2021 and a Chinese multicenter cohort

Article References: Aini, M., Yuan, Y., Liu, L., Yan, X., Li, J., Huang, S., Pan, B., & Tian, J. (2026). Epidemiological profile and factors associated with in-hospital mortality in neonatal heart failure: a secondary analysis of GBD 2021 and a Chinese multicenter cohort. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07826-y

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07826-y

Keywords: neonatal heart failure, Global Burden of Disease 2021, in-hospital mortality, congenital heart anomaly, China, multicenter cohort, Firth penalized logistic regression, years lived with disability, neonatology, severe infection, risk stratification, pediatric cardiology